Vaximm, a Swiss-German biotech company developing oral T-cell immunotherapies, has appointed Dr Jarl Ulf Jungnelius to the newly created position of Chief Medical Officer.
Jungnelius has spent more than 30 years practising medicine and leading key drug development projects for international pharmaceutical companies, with a focus on oncology.
He worked for nearly eight years at Celgene, most recently as Vice President Oncology, Global Solid Tumour Development TA Head. While at Celgene, he was also involved in the company’s immuno-oncology business development efforts. Prior to this he was at Pfizer, where he worked on a number of projects, serving as Executive Director, Full Development Team Leader, Oncology Clinical Development, Global Research and Development, responsible for several late-stage and early development programmes, including immune therapeutics.
Before that, he spent almost 10 years at Eli Lilly, rising to Arzoxifene Product Team Director and Chair of Lilly’s Breast Strategy Team.
In his various roles, Jungnelius’ responsibilities also included extensive interaction with regulatory authorities on a number of oncology programmes. Prior to joining the pharmaceutical industry, he worked as a clinical oncologist in the department of Oncology at the Karolinska Hospital in Stockholm, Sweden.
